复发性口腔鳞状细胞癌(OSCC)的挽救手术通常会导致生活质量(QOL)下降。本研究描述了三例导致西妥昔单抗联合放疗(CmabRT)良好的局部控制的病例。病例1在初次手术后4个月在右下乳突区出现OSCC区域复发。病例2在初次手术后7个月在腮腺区域出现OSCC局部复发。病例3在初次手术后1年和3个月出现咀嚼肌和Rouviere淋巴结OSCC局部复发。在所有情况下,进行Cmab+RT,无病生存期证实为4个月,2年6个月,Cmab+RT后10个月,分别。免疫组织化学,所有切除的肿瘤均未表达IA类磷脂酰肌醇3-激酶(PI3Kp110α)的110-kDa催化亚基。总之,如果复发性OSCC的抢救手术导致生活质量明显较低,然后转向放化疗可能是适当的治疗策略。此外,强有力的证据表明PI3Kp110α的表达与Cmab治疗效果相关。
Salvage surgery for recurrent oral squamous cell carcinoma (OSCC) often leads to a poor quality of life (QOL). The present study described three cases that resulted in favorable locoregional control with cetuximab in combination with radiotherapy (Cmab +
RT).
Case 1 had regional recurrence of OSCC at the lower right mastoid area 4 months after primary surgery.
Case 2 had regional recurrence of OSCC at the parotid area 7 months after primary surgery.
Case 3 had local recurrence of OSCC at the masticatory muscle and Rouviere\'s lymph nodes 1 year and 3 months after primary surgery. In all cases, Cmab + RT was performed, and disease-free survival was confirmed 4 months, 2 years and 6 months, and 10 months after Cmab +
RT, respectively. Immunohistochemically, all resected tumors had no expression of 110-kDa catalytic subunit of class IA phosphatidylinositol 3-kinase (PI3Kp110α). In conclusion, if salvage surgery for recurrent OSCC results in a significantly low QOL, then shifting to chemoradiotherapy may be appropriate as a treatment strategy. In addition, strong evidence indicated that PI3Kp110α expression is associated with Cmab therapy efficacy.